Brokerages Expect Agilent Technologies Inc (A) Will Post Quarterly Sales of $1.27 Billion

Brokerages expect Agilent Technologies Inc (NYSE:A) to announce $1.27 billion in sales for the current quarter, according to Zacks Investment Research. Six analysts have provided estimates for Agilent Technologies’ earnings. The lowest sales estimate is $1.26 billion and the highest is $1.27 billion. Agilent Technologies posted sales of $1.21 billion in the same quarter last year, which would indicate a positive year over year growth rate of 5%. The business is expected to report its next earnings results on Monday, May 13th.

According to Zacks, analysts expect that Agilent Technologies will report full year sales of $5.18 billion for the current fiscal year, with estimates ranging from $5.17 billion to $5.19 billion. For the next fiscal year, analysts forecast that the business will post sales of $5.49 billion, with estimates ranging from $5.45 billion to $5.52 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Agilent Technologies.

Agilent Technologies (NYSE:A) last posted its earnings results on Wednesday, February 20th. The medical research company reported $0.76 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.03. The company had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.27 billion. Agilent Technologies had a net margin of 22.86% and a return on equity of 19.90%. The business’s revenue for the quarter was up 6.0% compared to the same quarter last year. During the same period last year, the business posted $0.66 earnings per share.

A has been the topic of several analyst reports. Alembic Global Advisors lowered shares of Agilent Technologies to a “hold” rating in a report on Monday, December 31st. UBS Group initiated coverage on shares of Agilent Technologies in a report on Friday, March 15th. They issued a “buy” rating and a $92.00 target price on the stock. Zacks Investment Research upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating and set a $79.00 target price on the stock in a report on Monday, January 21st. Needham & Company LLC initiated coverage on shares of Agilent Technologies in a report on Wednesday, January 2nd. They issued a “buy” rating and a $77.00 target price on the stock. Finally, JPMorgan Chase & Co. increased their target price on shares of Agilent Technologies to $85.00 and gave the stock an “overweight” rating in a report on Thursday, February 21st. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $87.17.

In other Agilent Technologies news, SVP Michael Tang sold 6,728 shares of Agilent Technologies stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $80.50, for a total value of $541,604.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Paul N. Clark sold 2,823 shares of Agilent Technologies stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $80.31, for a total transaction of $226,715.13. Following the completion of the sale, the director now owns 88,857 shares in the company, valued at $7,136,105.67. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 83,722 shares of company stock worth $6,532,504.

Hedge funds have recently modified their holdings of the business. IFM Investors Pty Ltd grew its position in shares of Agilent Technologies by 9.4% in the 4th quarter. IFM Investors Pty Ltd now owns 18,362 shares of the medical research company’s stock valued at $1,239,000 after acquiring an additional 1,574 shares during the period. BTIM Corp. grew its position in shares of Agilent Technologies by 21.9% in the 4th quarter. BTIM Corp. now owns 58,267 shares of the medical research company’s stock valued at $3,931,000 after acquiring an additional 10,475 shares during the period. Fulton Bank N.A. grew its position in shares of Agilent Technologies by 8.6% in the 4th quarter. Fulton Bank N.A. now owns 4,587 shares of the medical research company’s stock valued at $309,000 after acquiring an additional 362 shares during the period. Standard Life Aberdeen plc grew its position in shares of Agilent Technologies by 13.2% in the 3rd quarter. Standard Life Aberdeen plc now owns 85,030 shares of the medical research company’s stock valued at $5,998,000 after acquiring an additional 9,889 shares during the period. Finally, Nordea Investment Management AB grew its position in shares of Agilent Technologies by 17.7% in the 3rd quarter. Nordea Investment Management AB now owns 18,394 shares of the medical research company’s stock valued at $1,298,000 after acquiring an additional 2,760 shares during the period.

A traded down $2.12 during mid-day trading on Friday, hitting $75.43. The stock had a trading volume of 4,034,820 shares, compared to its average volume of 1,841,301. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.79 and a current ratio of 3.39. The firm has a market cap of $25.53 billion, a PE ratio of 27.04, a price-to-earnings-growth ratio of 2.23 and a beta of 1.38. Agilent Technologies has a 1-year low of $60.42 and a 1-year high of $82.27.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 24th. Investors of record on Tuesday, April 2nd will be issued a dividend of $0.164 per share. The ex-dividend date of this dividend is Monday, April 1st. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.87%. Agilent Technologies’s payout ratio is 23.66%.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

Featured Article: How Do Front-End Loads Impact an Investment?

Get a free copy of the Zacks research report on Agilent Technologies (A)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.